Markenta Martial
Psychiatric/Mental Health · Orlando, FLNPI 1639889272
Payments from drug & device makers
Across 172 payments — averaging $23.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$544
- Johnson & Johnson$530
- Neurocrine Biosciences, Inc.$502
- Otsuka America Pharmaceutical, Inc.$411
- Vanda Pharmaceuticals Inc.$291
- plus $821 from 10 others
What the payments were for
- Food & beverage$4,120100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 40 | $1,020 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $544 |
| Johnson & Johnson | 28 | $530 |
| Neurocrine Biosciences, Inc. | 18 | $502 |
| Otsuka America Pharmaceutical, Inc. | 17 | $411 |
| Vanda Pharmaceuticals Inc. | 10 | $291 |
| Alkermes, Inc. | 15 | $234 |
| E.r. Squibb & Sons, L.L.C. | 7 | $162 |
| Axsome Therapeutics, Inc. | 6 | $136 |
| Bausch Health US, LLC | 3 | $64 |
| Teva Pharmaceuticals USA, Inc. | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $53 |
| Supernus Pharmaceuticals, Inc. | 3 | $48 |
| Bioxcel Therapeutics, Inc. | 1 | $25 |
| Noven Therapeutics, LLC | 1 | $20 |
| Luye Pharma (USA) Ltd. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,120 in reported general payments places this provider in the 85th percentile of 3,096 psychiatric/mental health providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 16 | $39,876 |
| VraylarCariprazine Hcl | 19 | $26,608 |
| RexultiBrexpiprazole | 18 | $25,961 |
| Aripiprazole | 23 | $5,820 |
| Vilazodone Hcl | 11 | $1,234 |
| Buspirone Hcl | 71 | $906 |
| Duloxetine Hcl | 50 | $633 |
| Quetiapine Fumarate | 73 | $535 |
| Alprazolam | 26 | $508 |
| Trazodone Hcl | 56 | $433 |
| Bupropion XlBupropion Hcl | 36 | $366 |
| Olanzapine | 19 | $359 |
| Gabapentin | 24 | $353 |
| Lamotrigine | 65 | $309 |
| Hydroxyzine Hcl | 15 | $295 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $411 | $65,83634 claims |
| AbbVieVraylar | $1,020 | $26,60819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,096 psychiatric/mental health providers in Florida.
Other psychiatric/mental health in Orlando
- Elizabeth GueldeOrlando$48K
- Amber SiegelOrlando$17K
- Orville MurrayOrlando$13K
- Roger RiveraKissimmee$1.6M
- Bethanie Simmons BecilJacksonville$782K
- Hannah PhillipsMaitland$455K
- Cheedy JajaTampa$266K
- Scott DurrancePensacola$224K
- Eudaldo AponteHialeah$214K
- Heather WarrenTallahassee$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.